Health Care • Biotechnology: Pharmaceutical Preparations
$12.57 ▲ +0.26
(+2.11%)
MKT CAP: $1.07B • VOL: 4.10M
52W L $9 52W H $23
ROARABLE / RQD
D • 46/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$11
MEDIAN
$14
MEAN
$14
HIGH
$17
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MLTX TAPE
MLTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $15.21 | $14.46 | 2025-02-14 | $11.44 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $15.84 | $14.83 | 2025-02-06 | $11.82 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $14.33 | $13.83 | 2025-01-29 | $12.07 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $12.82 | — | 2025-01-17 | $12.32 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $11.06 | $11.94 | 2025-01-09 | $11.19 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $14.96 | $13.07 | 2024-12-18 | $10.94 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $12.19 | $12.70 | 2024-12-04 | $11.69 | -4.3% | 48% | C |